Business Description
Axsome Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05464T1043
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.75 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 1.32 | |||||
Debt-to-EBITDA | -0.66 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.37 | |||||
Beneish M-Score | -2.04 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22.5 | |||||
3-Year EPS without NRI Growth Rate | -17.3 | |||||
3-Year FCF Growth Rate | -15 | |||||
3-Year Book Growth Rate | 9.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 62.42 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59.18 | |||||
9-Day RSI | 54.01 | |||||
14-Day RSI | 52.44 | |||||
6-1 Month Momentum % | 10.38 | |||||
12-1 Month Momentum % | 1.19 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.2 | |||||
Quick Ratio | 3.09 | |||||
Cash Ratio | 2.3 | |||||
Days Inventory | 170.38 | |||||
Days Sales Outstanding | 112.51 | |||||
Days Payable | 595.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.2 | |||||
Shareholder Yield % | -9.51 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 90.12 | |||||
Operating Margin % | -97.62 | |||||
Net Margin % | -118.07 | |||||
FCF Margin % | -77.15 | |||||
ROE % | -148.91 | |||||
ROA % | -54.17 | |||||
ROIC % | -226.08 | |||||
ROC (Joel Greenblatt) % | -4597.26 | |||||
ROCE % | -68.96 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 13.87 | |||||
PB Ratio | 24.63 | |||||
Price-to-Tangible-Book | 44.18 | |||||
EV-to-EBIT | -11.64 | |||||
EV-to-Forward-EBIT | -18.26 | |||||
EV-to-EBITDA | -11.93 | |||||
EV-to-Forward-EBITDA | -18.93 | |||||
EV-to-Revenue | 13.58 | |||||
EV-to-Forward-Revenue | 8.77 | |||||
EV-to-FCF | -17.63 | |||||
Price-to-Net-Current-Asset-Value | 60.29 | |||||
Earnings Yield (Greenblatt) % | -8.59 | |||||
FCF Yield % | -5.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Axsome Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 231.849 | ||
EPS (TTM) (€) | -5.89 | ||
Beta | 0.43 | ||
Volatility % | 38.14 | ||
14-Day RSI | 52.44 | ||
14-Day ATR (€) | 1.526727 | ||
20-Day SMA (€) | 69.031 | ||
12-1 Month Momentum % | 1.19 | ||
52-Week Range (€) | 53.42 - 91.9 | ||
Shares Outstanding (Mil) | 47.5 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Axsome Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Axsome Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Axsome Therapeutics Inc Frequently Asked Questions
What is Axsome Therapeutics Inc(FRA:19X)'s stock price today?
When is next earnings date of Axsome Therapeutics Inc(FRA:19X)?
Does Axsome Therapeutics Inc(FRA:19X) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |